100 completed. 100 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 100 | Completed 100 |
| Phase 2 | 19 | Completed 19 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine - Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2017-03-17 | 2023-01-18 |
| Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 1 / Phase 2 | Completed | University of Nebraska | 54 | 2015-09-28 | 2023-12-13 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Enasidenib - Solid Tumor, Glioma | Phase 1 / Phase 2 | Completed | Celgene | 21 | 2014-12-08 | 2021-02-23 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II) - Peripheral T-cell Lymphomas (PTCL), PTCL-NOS | Phase 1 / Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 89 | 2014-09-01 | 2026-08-19 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma carfilzomib - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | University of Nebraska | 15 | 2011-06-21 | 2023-09-15 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma imetelstat sodium, laboratory biomarker analysis, pharmacological study - Brain and Central Nervous System Tumors, Lymphoma | Phase 1 | Completed | Children's Oncology Group | 34 | 2011-05-01 | 2014-01-30 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma everolimus, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 58 | 2011-01-10 | 2020-10-22 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer bortezomib, nelfinavir mesylate - Leukemia, Lymphoma | Phase 1 | Completed | Swiss Cancer Institute | 18 | 2010-07-01 | 2019-05-15 |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 46 | 2010-07-01 | 2015-03-03 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
Showing 20 of 100. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (96) · Lymphoma, Large B-Cell, Diffuse (81) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (81) · Lymphoma, Follicular (80) · Lymphoma, Mantle-Cell (80) · Hodgkin Disease (79) · Lymphoma, B-Cell, Marginal Zone (79) · Burkitt Lymphoma (78) · Leukemia, Lymphocytic, Chronic, B-Cell (77) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (77) · Lymphoma, Non-Hodgkin (74) · Lymphoma, Large-Cell, Immunoblastic (72) · Lymphoma, T-Cell, Cutaneous (71) · Mycosis Fungoides (70)
Hemic and Lymphatic Diseases (100) · Immune System Diseases (100) · Immunoproliferative Disorders (100) · Lymphadenopathy (100) · Lymphatic Diseases (100) · Neoplasms by Histologic Type (100) · Neoplasms (97) · Lymphoproliferative Disorders (95) · Hematologic Diseases (89) · Leukemia, Lymphoid (88) · Lymphoma, T-Cell (88) · Lymphoma, B-Cell (85) · Disease Attributes (80) · Pathologic Processes (80) · Pathological Conditions, Signs and Symptoms (80)
Cyclophosphamide (7) · Bortezomib (6) · Peripheral Blood Stem Cell Transplantation (6) · Carboplatin (5) · Doxorubicin (5) · Etoposide (5) · Everolimus (5) · Filgrastim (5) · Prednisone (5) · Vorinostat (5) · fludarabine phosphate (5) · Cyclosporine (4) · Lenalidomide (4) · Paclitaxel (4) · Vincristine (4)
National Cancer Institute (NCI) (28) · National Institutes of Health Clinical Center (CC) (6) · Memorial Sloan Kettering Cancer Center (5) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Fred Hutchinson Cancer Center (2) · Massachusetts General Hospital (2) · NYU Langone Health (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · SWOG Cancer Research Network (2) · University of Nebraska (2) · University of Wisconsin, Madison (2) · Vion Pharmaceuticals (2) · Acrotech Biopharma Inc. (1)
United States (93) · Italy (4) · Canada (3) · France (2) · Germany (2) · South Korea (2) · China (1) · Switzerland (1) · United Kingdom (1)
Shivaani Kummar, MD (4) · David R. Spriggs, MD (2) · Leonard B. Saltz, MD (2) · Mace L. Rothenberg, MD, FACP (2) · Mario Sznol, MD (2) · Michael A. Carducci, MD (2) · Ramesh Ramanathan (2) · Alan P. Venook, MD (1) · Alex A. Adjei, MD, PhD (1) · Alex Shalaurov, MD, PhD (1) · Amir Mortazavi, MD (1) · Amy Kimball, MD, PhD (1) · Angela Davies, MD (1) · Barbara Hicks (1) · Beata Holkova, MD (1)
PMID 32499241, PMID 11410496, PMID 14630685, PMID 16135477, PMID 17119113, PMID 18327587, PMID 18463792, PMID 19451403, PMID 19789320, PMID 21247755, PMID 21498721, PMID 22259028, PMID 24057042, PMID 24352795, PMID 24474568, PMID 24530972, PMID 25213183, PMID 26659919, PMID 26943915, PMID 28103725, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29622656, PMID 31617432, PMID 33492438, PMID 37939262, PMID 39821757, PMID 9628848
U01CA099168 (4), P30CA014520 (3), P30CA016672 (3), U01CA062487 (3), U01CA062491 (3), U01CA062505 (3), U10CA032102 (3), P30CA008748 (2), P30CA015083 (2), P30CA015704 (2), P30CA016058 (2), P30CA016087 (2), P30CA033572 (2), P30CA036727 (2), U01CA062502 (2)